

<u>Toowoomba</u>







Му News 💄

Today's Paper

Local QLD National World Opinion Business Entertainment Lifestyle Sport

Q

BREAKING

WATCH: CCTV captures teens smashing in supermarket door

Health Conditions Dementia

Alzheimer's disease: World Health Frontal lobe Amyloid plaque **Hippocampus** Xanamem


A once-a-day pill that targets the production of the stress hormone cortisol in the brain has the potential to be the "holy grail" in the treatment of Alzheimer's disease, Australian researchers say. Xanamem, a new therapy...

A once-a-day pill that could be the "holy grail" in the treatment of Alzheimer's


Join the conversation (15 Comments)

mustranan inini benina the potential wonder arag.

The World Health Organisation has granted Actinogen Medical the More related stories nonproprietary name, or generic name, 'emestedastat' for its new drug



How a change in your eye can detect dementia and diabetes



Xanamem has been granted a nonproprietary name by the World Health Organisation. Picture: AFP)

The four things you can do now to delay dementia


Randa win helpestion wowlf-first course of Alzneimers disease and addressur key areas experienced major benefits expected to delay dementia's onset. cognitive decline.



front otemporal dementia, and dementia associated with Parkinson's disease, Actinogen's CEO Professor Steve Gourlay said. This tool can predict if and when you'll get early Alzheimer's disease

A new online tool has been able to predict what age older adults will get Alzheimer's. And it may give people the chance to plan their dementia care while they are still able to.





it's not the brand name, it's the name that will always be used for that 'No clear message': particular drug,' he said. Council faces heat over


big carnival changes

Shows you don't want to

in iss this week what's unique about our situation is that in giving us the new na emestedastat, the committee recognised that this is the first of its be named in this way."



Dr Steven Gourlay is the CEO of Actinogen Medical. Picture: Supplied



 ${\tt PET\, scan\, images\, show\, the\, cortisol-producing\, enzyme\, in\, the\, brain,\, which\, the\, Xananem\, pill\, targets.}$

Dr Gourlay said Actinogen was bringing "a truly novel and innovative therapy" to patients and the hope was that the drug would be applicable not just to Alzheimer's but to other types of dementia as well as potentially Parkinson's, depression and other related psychiatric illnesses.

Alzheimer's disease, which results in worsening symptoms over a number of years, affected 411,100 Australians in 2023, according to Australian Institute of Health and Welfare estimates.

Associate Professor Michael Woodward AM, Dementia Australia's Honorary Medical Adviser, said Xanamem "may offer stabilisation and hopefully a slower decline for people living with dementia".

Associate Professor Woodward said anything that could safely and conveniently assist to reduce the impact of Alzheimer's disease was "welcome progress".

"Xanamem has solid data from early-stage studies showing that it is effective," he said.

"It would certainly be welcomed to have a new class of orally active drug that helps people living with dementia manage their condition."

For anyone who is impacted by dementia, has questions or needs advice, the National Dementia Helpline is available 24 hours a day, seven days a week on 1800 100 500 or visit <u>dementia.org.au</u> for email or live chat options.

More Coverage



'Epidemic': New DIY Aussie game-changing STI test



'Worried for her': Fears for Bianca Censori after Grammys

Originally published as <u>Alzheimer's disease: World Health Organisation win</u> <u>for Actinogen Medical drug Xanamem</u>

Membership About Us Contact Us Our News Our Partners Our Apps Network Group/Corporate About Us Help & support Buy Search Sell Subscriptions Classifieds Courier Mail Meet the Team FAQs Herald Sun Job Standards of Opportunities Newsletters Hipages practice The Daily Telegraph My Tributes Code of Conduct Letter to the Kayo Editor The Advertiser My Tributes Rewards Subscription Licensing & news.com.au Punters Reprints Subscription Gold Coast odds.com.au Advertise with us Bulletin terms racenet.com.au Financial The Cairns Post Hardship Policy Sky News Townsville Coupons Bulletin NT News The Mercury Geelong Advertiser The Weekly Times CODE Sports

A NOTE ABOUT RELEVANT ADVERTISING: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. Find out more about our policy and your choices, including how to opt-out. Sometimes our articles will try to help you find the right product at the right price. We may receive payment from third parties for publishing this content or when you make a purchase through the links on our sites.

Nationwide News Pty Ltd @ 2025. All times AEST (GMT +10). Powered by WordPress.com VIP

Privacy policy

Relevant ads opt-out

Cookie policy

Terms of us